Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06593457 · ClinicalTrials.gov registry record · Phase 1
A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects
A Phase 1 study, sponsored by Nurix Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT06593457 is a Phase 1 study that has completed, run by Nurix Therapeutics. The registered enrollment target is 32 participants.
The verdict
NCT06593457, a Phase 1 study, has completed, sponsored by Nurix Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This is a Phase 1, 2-part double-blinded (with respect to NX-5948/placebo), placebo-controlled study. Part 1 is a randomized, 3 period cross-over food-effect (FE) and drug-drug interaction (DDI) study. Part 2 is a single-period PK evaluation study.
Interventions
- DRUG Matching Placebo
- DRUG IP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2024-08-20 |
| Est. Completion | 2024-11-14 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06593457
The ClinicalTrials.gov registry entry for NCT06593457 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nurix Therapeutics, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT06593457 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06593457 about?
NCT06593457 is a clinical study titled "A Food-Effect, Drug-Drug Interaction, and Pharmacokinetics Study of NX-5948 in Healthy Adult Subjects". This is a Phase 1, 2-part double-blinded (with respect to NX-5948/placebo), placebo-controlled study. Part 1 is a randomized, 3 period cross-over food-effect (FE) and drug-drug interaction (DDI) study. Part 2 is a single-period PK evaluation study.
What is the current status of trial NCT06593457?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2024-08-20. Estimated completion is 2024-11-14.
What interventions are being tested in trial NCT06593457?
The interventions under investigation include: Matching Placebo (DRUG), IP (DRUG).
Who is sponsoring clinical trial NCT06593457?
This trial is sponsored by Nurix Therapeutics, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.